

Supplemental Table 2 Summary of findings table: laboratory test and clinical indexes.

Outcomes	No of participants (studies)	Quality of the evidence (GRADE)	Effect	Heterogeneity		Overall effect	
			Relative (95% CI) or absolute	I ²	P	Z	P
Liver function							
AST[47, 49, 51, 53, 55]	370 (5)	⊕⊕OO LOW	MD 42.72 lower (71.91 to 13.52 lower)	84%	<0.0001	2.87	0.004
ALT[47, 49, 51, 53-55]	682 (6)	⊕⊕⊕O MODERATE	MD 27.66 lower (54.31 to 1.01 lower)	85%	<0.00001	2.03	0.04
Tbil[47, 49, 51, 53-55]	682 (6)	⊕⊕⊕O MODERATE	MD 0.97 lower (2.5 lower to 0.57 higher)	56%	0.05	1.23	0.22
Alb[47, 49, 51, 53-55]	682 (6)	⊕⊕⊕O MODERATE	MD 0.42 higher (0.26 to 0.57 higher)	0	0.71	5.31	<0.00001
Makers of inflammation							
WBC[49, 54, 55]	434 (3)	⊕⊕⊕O MODERATE	MD 0.93 lower (1.6 to 0.26 lower)	34%	0.22	2.71	0.007
TNF-α[50, 52, 53]	129 (3)	⊕⊕OO LOW	MD 0.01 lower (15.08 lower to 15.06 higher)	53%	0.12	0	1
IL-6[49, 50, 52, 53]	211 (4)	⊕⊕OO LOW	MD 11.37 lower (14.62 to 8.13 lower)	0	0.46	6.87	<0.00001
IL-2[49, 50]	118 (2)	⊕⊕OO LOW	MD 20.72 lower (50.34 lower to 8.89 higher)	0	0.51	1.37	0.17
Markers of immune system							
IgA[47, 49, 52]	178 (3)	⊕⊕OO LOW	MD 0.2 higher (0 to 0.4 higher)	0	0.79	1.96	0.05
IgG[47, 49]	148 (2)	⊕⊕OO LOW	MD 0.36 lower (1.47 lower to 0.75 higher)	39%	0.20	0.63	0.53
IgM[47, 49, 52]	178 (3)	⊕⊕OO LOW	MD 0 higher (0.11 lower to 0.1 higher)	21%	0.28	0.05	0.96
CD3[49, 52]	112 (2)	⊕⊕OO LOW	MD 0.94 higher (6.76 lower to 8.64 higher)	87%	0.005	0.24	0.81
Clinical indexes							
Infection [47, 49, 51, 53, 54]	642 (5)	⊕⊕⊕O MODERATE	OR 0.44 (0.28 to 0.68)	0	0.91	3.66	0.0003
biliary leakage [51, 54]	431 (2)	⊕⊕⊕O MODERATE	OR 0.71 (0.32 to 1.59)	0	0.94	0.83	0.41
Duration of hospital stay [47, 49, 51, 53, 54]	366 (5)	⊕⊕OO LOW	MD 2.17 lower (3.04 to 1.3 lower)	49%	0.10	4.90	<0.00001
Mortality [47, 49, 51, 53, 54]	642 (5)	⊕⊕OO LOW	OR 0.25 (0.06 to 1.03)	0	0.94	1.92	0.06